Viral infections are a major cause of morbidity and mortality after organ transplantation, when cytomegalovirus (CMV), Epstein-Barr virus (EBV), and adenovirus infections are particularly common."2 CMV has been studied extensively, and its potential for transfer with the donor organ3 and for reactivation with immunosuppression4 is well recognised in renal,5 bone marrow, heart67 and liver transplant recipients.8 EBV and adenovirus, although not transmitted with the donor organ, have similar potential and may cause serious disease after organ transplantation.9 There is also increasing evidence associating EBV infection with the subsequent development of lymphoproliferative disorders. '°" Toxoplasma gondii can also be transmitted with the donor organ, and fatal disseminated disease has been reported after heart, renal, and liver transplantation in adults. '2-'4 The impact of these infections in children after liver transplantation has not In all children intravenous cyclosporine was started 48 to 72 hours after transplantation, in a dose of 2 mg/kg/day increasing to 4 mg/kg/day. This was changed to oral cyclosporine, 10 mg/ kg/day, in the second week when the T-tube was clamped. Methylprednisolone, 10 mg/kg, was given intraoperatively and prednisolone (2 mg/kg/day initially, reducing to 1 mg/kg/ day by two weeks), and azathioprine (1 5 mg/ kg/day) were started immediately after the operation. Episodes of acute rejection were treated with intravenous methylprednisolone, 1-0 g/1-76 m2/day for three days. Immunosuppression was reduced or temporarily withdrawn during episodes of severe infection.
Samples for serological analysis were taken before transplantation, then weekly throughout the hospital admission, and on subsequent follow up visits. Serum samples were also available from 25 donors.
Serological tests were performed to detect antibodies to CMV, EBV, adenovirus, herpes simplex virus (HSV), varicella zoster virus (VZV) and Tgondii.
The complement fixation test (CFT) was performed as described by Bradstreet and Taylor,'6 with three 5000 haemolytic doses of guinea pig complement to detect antibody to CMV, HSV, VZV and adenovirus. Sera before and after transplantation from each patient were titrated in parallel.
To detect CMV antibody in those sera with a CMV complement fixation titre of less than 8, and in certain others which showed anomalous CMV complement fixation titres, the more sensitive competitive enzyme linked immunosorbent assay (ELISA), as CMV was isolated from urine culture in three patients. The donor CMV antibody status was not known for all cases, particularly those who received a transplant before 1986. Since then the importance of the donor organ in transmission of CMV has been recognised. Three of the five children who developed primary CMV infection received organs from CMV positive donors. The donor CMV antibody status was not known for the other two. Only one child who was CMV antibody negative, and was known to have received a CMV positive organ failed to acquire primary infection.
All children with primary CMV infection had clinically important disease. The main clinical features of the infection are summarised in table 2. The three patients who developed infection within one month of liver transplantation had severe disease. One child died with pneumonitis and encephalitis 47 days after transplantation. Another, who had received methylprednisolone for an episode of acute rejection, subsequently developed CMV hepatitis; liver function was abnormal for six months but has remained normal since. The third child developed moderately severe pneumonitis and duodenal ulceration. Each of these children was treated with Cymevene (ganciclovir) soon after the onset of symptoms.
Reactivated CMV infection arose in eight (47 O%) of the 17 children who were seropositive before transplantation. In six this occurred within four weeks of transplantation during the time of maximal immunosuppression, in one at eight weeks, and in the last at seven months during a terminal episode of septicaemia. Only two children were symptomatic. The symptoms were mild and included fever of one to three weeks' duration, anorexia and diarrhoea, coinciding with the rise in CMV complement fixation antibody titre, development of CMV specific IgM (< 10 units), and isolation of CMV from the urine.
EPSTEIN-BARR VIRUS (EBV)
Of the 39 children from whom serum was available, 22 were seronegative before transplantation. Of these, 12 showed a > 16-fold rise in antibody to EBV viral capsid antigen. In two patients who showed a minimum 16-fold rise in necropsy. Four other children had symptoms associated with adenovirus infection. All had fever of about one week's duration, coryza, pharyngitis and conjunctivitis. One child also had a prominent mobilliform rash.
HERPES SIMPLEX VIRUS
There were no primary infections with HSV in this series, but three of the 10 children who were seropositive preoperatively had subsequent reactivated HSV infection. Mucosal ulceration was present in all cases. Two of these had associated fever in the early period after surgery at four and eight weeks, respectively, and were treated with intravenous Zovirax (acyclovir). A significant (> four-fold) rise in HSV antibody titre was shown in all cases and HSV was isolated in two. In a fourth child HSV was isolated without a noticeable change in antibody titre or symptoms.
VARICELLA ZOSTER VIRUS
One child developed chicken pox after contact with a brother with the disease. She had two brief grand mal convulsions, but no VZV antibody was found in the cerebrospinal fluid. The immunosuppression was interrupted; she was treated with zoster hyperimmune globulin and acyclovir and recovered without sequelae.
RESPIRATORY SYNCYTIAL VIRUS
Respiratory syncytial virus infection was found in one child who developed moderately severe bronchiolitis eight weeks after transplantation, 10 days after recovering from EBV infection.
T GONDII INFECTION
Tgondii infection was diagnosed serologically in only one patient who showed a > four-fold rise in latex agglutination T gondii antibody titre (table 3) . This child, who was T gondii antibody negative before transplantation, received an organ from an antibody positive donor. The rise in titre occurred three weeks later, one week after the withdrawal of immunosuppressive treatment because of a left hepatic lobe abscess. This was after treatment for acute rejection with methylprednisolone. Treatment with pyrimethamine was given for six weeks. There were, however, no clinical symptoms or signs which could be ascribed to this infection.
Discussion
The aim of this study was to assess the impact of viral and T gondii infections on our paediatric liver transplant recipients and to describe some of the patterns of clinical disease associated with these infections. Our findings will be compared with those of other series, in particular, those of Breinig et al. '5 CMV is the most common viral cause of morbidity in immunosuppressed patients, including all organ transplant recipients. A high incidence of CMV infection has been reported in adult series for kidney (50-96%), 3 4 liver (50-77%),' 26 and heart (48 %)12 transplantation. In our study CMV was responsible for most of the severe morbidity experienced and for one of the two fatal viral infections.
Thirty per cent ofour study group developed CMV infection, and primary infection was seen in 19% (five of 26) of CMV antibody negative children. This is comparable with the findings ofBreinig et al"5 and also with those ofour adult liver transplant series (table 4) . Reactivated CMV infection was found in eight of 17 (47%o) (table 4) . Children who had primary CMV infection experienced the most serious disease, with one fatality. Only mild symptoms were experienced by the two symptomatic patients who had reactivated infection. In contrast, the Pittsburgh group found that primary CMV infection occurred less frequently in their paediatric recipients than in adults. They also found a significantly higher incidence of reactivated CMV infection in both children and adults.
The incidence of CMV antibody increases with age from 5-20% at 12 months,27 28 Eighty per cent (eight of 10) of the children in our series who experienced primary infection were less than 3 years old. Hence this age group has a potentially increased risk of long term sequelae resulting from primary EBV infection.
Adenovirus infection causes a wide spectrum of illness in children. 33 It has also been recognised as a cause of fulminant hepatitis and disseminated life threatening disease in immunocompromised hosts, including bone morrow, renal,3' and liver transplant recipients.'°.
We found adenovirus infection in eight of 43 (I9 %) recipients, which is comparable with the incidence reported by Koneru et al of 22/262 or 8-4% in a large study of adenovirus infection in paediatric liver transplant recipients.9 Their study relied on viral culture and isolation methods alone; we used chiefly serological evidence, with viral isolation and therefore typing in only two cases. Adenovirus types 1 and 2 accounted for 60% of isolates in Koneru's study and were responsible only for mild illness. All five patients who experienced adenovirus type 5 infection had severe fulminant hepatitis, all following treatment for rejection, and two patients died. Adenovirus type 7 was isolated only in one case and was associated with only mild disease. In our study the one child who had adenovirus type 7 infection had severe disseminated disease leading to fatal respiratory and hepatic failure.
Evidence of EBV infection in three cases, and CMV in one, was found simultaneously or within four weeks of adenovirus infection, suggesting an association between these infections in immunosuppressed patients. Such an association after organ transplantation has been documented.9 15 No specific treatment is available for adenovirus infection, although some therapeutic measures have been reported.3536 We recently found in vitro evidence of a response to ganciclovir.36 Reduction of immunosuppressive treatment is essential and, to date, the only effective means of reducing morbidity.
Toxoplasma gondii has not been reported as a cause ofmorbidity in children who have undergone transplantation. In Cambridge the greatest incidence of T gondii infection has been found in heart transplant recipients.7 12 Fifty seven per cent of those who were mismatched developed primary donor acquired infection, two ofwhom died of disseminated disease. One of two cases in the adult liver transplant series was also fatal. 8 The child in our series who was infected with T gondii was asymptomatic. The mild course of the infection may be explained by the concomitant reduction of immunosuppressive treatment and pyrimethamine.
In conclusion, this study confirms that CMV infection is the principal cause of serious viral disease in children after liver transplantation. EBV, adenovirus, and T gondii infection also have the potential for producing serious disease. Surveillance for these infections and for long term sequelae should be included in the follow up of all children after transplantation.
It is important to screen donors for CMV and T gondii infection and to avoid donor/recipient mismatch whenever possible.
